Saudi Arabia · Obesity · GLP-1 market research

Obesity & GLP-1 Market Research in Saudi Arabia

BioNixus runs obesity and GLP-1 market research in Saudi Arabia — including GLP-1 physician surveys, KAP and ATU tracking, patient-journey and persistence studies, and payer/access interviews. Fieldwork covers endocrinology, family medicine, bariatric/metabolic surgery, and obesity clinics, with senior-led delivery from our Al Khobar office. Custom studies typically range from $10,000 to $60,000. Proposal within one working day.

Physician surveys, KAP and ATU tracking, semaglutide and tirzepatide access, and patient persistence — custom primary research from Al Khobar.

Last reviewed 5 October 2026

Request a $10,000–$60,000 scoped proposal See what we research

$10,000–$60,000

custom studies

~3,200

physicians in network

~70

studies in 2026

Al Khobar

Saudi fieldwork office

Quick answer

What does BioNixus do for obesity and GLP-1 market research in Saudi Arabia?

BioNixus is a custom primary-research firm for pharmaceutical and healthcare teams that need obesity GLP-1 market research in Saudi Arabia. We do not sell syndicated obesity report price packs.

GLP-1 physician surveys and KAP studiesGLP-1 and anti-obesity medicine physician surveys and KAP studies in Saudi Arabia, commissioned for a brand decision.
Semaglutide and tirzepatide modulesInitiation, switching, and indication-mix questions on semaglutide and tirzepatide, including diabetes versus obesity use.
SFDA, NUPCO, and CHI access contextPayer and formulary interviews that separate public, insured, and self-pay routes for weight-management therapy.
Patient journey and discontinuationPatient journey and discontinuation research on initiation, persistence, and reasons patients stop therapy.
Bariatric referral and pharmacotherapyHow bariatric referral interacts with pharmacotherapy across surgery, clinic, and prescribing pathways.
Arabic and English fieldworkArabic and English fieldwork with Al Khobar–supported delivery for Saudi obesity and GLP-1 programmes.

BioNixus GLP-1 physician surveys in Saudi Arabia stratify endocrinology, family medicine, internal medicine, and bariatric surgery; instruments run in Arabic or English; custom projects typically cost $10,000–$60,000. BioNixus works with about 3,200 physicians across its healthcare network and expects about 70 studies in 2026.

Cited figures

Key figures for Saudi obesity and GLP-1 market research

Independent national survey of Saudi clinicians (n=92; 2024 fieldwork published on PMC): endocrinologists prescribed anti-obesity medicines more frequently than family physicians (90.0% vs 60.5%); GLP-1 receptor agonists were the most commonly reported first-line anti-obesity medicines. This is an independent academic survey, not a BioNixus study. PMC12366907
BioNixus delivery facts: about 3,200 physicians in the healthcare network; about 70 studies in 2026; custom obesity and GLP-1 projects typically $10,000–$60,000.

Coverage

What BioNixus runs for obesity market research in Saudi Arabia

GLP-1 physician surveys and KAP studies

Commissioned physician surveys among endocrinology, family medicine, internal medicine, bariatric surgery, and obesity-clinic physicians on initiation, monitoring, and comfort with anti-obesity medicines.

Semaglutide and tirzepatide initiation and switching

Molecule-level questions on semaglutide and tirzepatide: dose escalation, diabetes versus obesity indication mix, supply interruptions, and self-pay versus covered use.

SFDA, NUPCO, and CHI access interviews

Payer and formulary interviews on public procurement, Council of Health Insurance (CHI) plan design, prior authorisation, and out-of-pocket exposure.

Patient journey and discontinuation research

Where patients first seek help, what they expect, and how cost, tolerability, and monitoring burden drive discontinuation.

Bariatric referral and pharmacotherapy

Referral routes into surgery and how pharmacotherapy substitutes for, delays, or complements bariatric and metabolic procedures.

Pharmacy channel and supply behaviour

Dispensing across retail and hospital pharmacies, stock behaviour during constrained supply, and cash-pay dynamics for incretin therapies.

Breakdown

Competing treatment routes in Saudi obesity market research

Prescription anti-obesity medicines

Incretin-based and other approved weight-management therapies. Physician survey work tracks access route, monthly cost exposure, and persistence.

Bariatric and metabolic surgery

Sleeve gastrectomy, bypass, and revisional procedures across public and private centres, and how surgical demand responds to effective pharmacotherapy.

Endoscopic and device-based interventions

Intragastric balloons, endoscopic sleeve procedures, and related devices positioned between lifestyle management and definitive surgery.

Obesity clinics and multidisciplinary programmes

Physician-led weight-management services combining pharmacotherapy, dietetics, behavioural support, and monitoring, usually sold as private packages.

Adjacent consumer and OTC categories

Meal replacement, nutraceutical, and wellness products that shape patient expectations and compete for the same out-of-pocket budget.

What is moving

Demand context for obesity market research in Saudi Arabia

High metabolic disease burden

Obesity and type 2 diabetes prevalence in the Gulf is among the highest globally, creating a large clinically eligible population across public and private sectors.

Incretin-based therapy availability

Effective pharmacological weight management has shifted patient expectations and brought previously untreated people into active medical care.

Vision 2030 and Quality of Life Program

National priorities on physical activity, nutrition, and healthy weight legitimise investment in prevention and weight management.

Established bariatric surgery capacity

Surgical capability in public and private centres means patients have a definitive option, so treatment-route competition is direct.

Private insurance under CHI

Council of Health Insurance (CHI) cover across the private workforce is a potential funding route, though weight-management coverage remains inconsistent.

Self-pay demand

A substantial share of pharmacotherapy and clinic demand is out of pocket, so price sensitivity and persistence sit at the centre of any forecast.

Market structure

Access structure for obesity market research in Saudi Arabia

The Saudi obesity conversation is no longer GLP-1 in the abstract. Commercial teams brief research on semaglutide (injectable weight-management and diabetes brands in class) and tirzepatide (dual GIP/GLP-1), alongside other incretin-based and legacy anti-obesity medicines. BioNixus physician surveys ask molecule-level questions: initiation criteria, dose escalation, switching between semaglutide and tirzepatide, diabetes versus obesity indication mix, supply interruptions, and self-pay versus covered use.

The Saudi Food and Drug Authority (SFDA) governs registration, quality, and safety communications for GLP-1 receptor agonists. BioNixus maps how SFDA registration status and safety communications affect willingness to initiate semaglutide or tirzepatide. Public volume for obesity and metabolic therapies often depends on NUPCO tendering and institutional formulary uptake, not retail awareness alone.

Access — not awareness — still decides addressable volume for anti-obesity medicines in Saudi Arabia. Public pathways depend on formulary and procurement (including NUPCO-linked supply). Private pathways sit under Council of Health Insurance (CHI) plan design, where weight-management therapy is often treated between medical necessity and lifestyle care. The remainder is out-of-pocket through retail pharmacy and private obesity clinics. BioNixus payer and physician research separates public, insured, and self-pay routes before any forecast is locked.

Three treatment routes compete for the same patient: prescription pharmacotherapy, bariatric and metabolic surgery, and obesity clinic programmes. Prescribing is distributed across endocrinologists, family physicians, internal medicine, bariatric surgeons, and obesity-clinic physicians. A physician survey that models only one route or one specialty misreads the market.

NUPCO Saudi Arabia tendering guide

Signals

Regional notes for a GLP-1 physician survey in Saudi Arabia

Riyadh

Deepest concentration of endocrinology capability, bariatric centres, and premium obesity clinics, and the market where private weight-management pricing is set.

Jeddah and the Western Region

Strong bariatric surgery tradition and dense private clinic competition, with a large insured population and active self-pay weight-management demand.

Eastern Province

Dammam and Al Khobar combine employer-insured coverage and company-linked healthcare with corporate wellness programmes that surface undiagnosed metabolic risk. Saudi fieldwork is coordinated from the Al Khobar office.

Secondary cities and interior regions

Growing clinic presence with heavier reliance on family physicians and greater out-of-pocket sensitivity, where persistence on therapy is typically the binding constraint.

Fieldwork

Who we interview for Saudi GLP-1 physician surveys

Endocrinologists and metabolic physicians

Clinical leaders in weight management, interviewed on patient selection, dose escalation, monitoring, and long-term therapy expectations.

Family physicians and internal medicine

High-volume initiators interviewed on referral thresholds, confidence with anti-obesity medicines, and practical barriers to prescribing.

Bariatric and metabolic surgeons

Surgeons whose referral relationships and procedure volumes are affected by pharmacotherapy, interviewed on patient selection and combined pathways.

Obesity-clinic physicians and pharmacists

Private obesity-clinic physicians and pharmacists interviewed on package design, dispensing, supply interruptions, and cash-pay behaviour.

Payers and insurance medical directors

Medical directors under Council of Health Insurance (CHI) regulated plans, researched on weight-management coverage policy and prior authorisation.

Patients and treatment considerers

People currently treated or actively seeking weight management, researched on journey, expectations, cost tolerance, and reasons for discontinuation.

BioNixus Saudi fieldwork is coordinated from Al Khobar (Eastern Province). Regional hubs also support programmes from Dubai (Thuraya Tower 1, 5th Floor, Al Sufouh 2), MENA Cairo, London, Sheridan WY (US), and São Paulo.

Physician survey

GLP-1 physician survey methodology in Saudi Arabia

BioNixus designs GLP-1 physician surveys in Saudi Arabia as commissioned primary research, scoped to the brand decision. A typical instrument covers the modules below.

Screeners: specialty, sector (public or private), region (Riyadh, Jeddah and the Western Region, Eastern Province including Al Khobar and Dammam, secondary cities), and monthly obesity or metabolic caseload.
KAP modules: guideline familiarity; comfort initiating anti-obesity medicines; perceived barriers such as training, supply, cost, and stigma.
Prescribing behaviour: share of eligible patients offered an anti-obesity medicine; first-line choice among semaglutide, tirzepatide, and other agents; diabetes versus obesity indication mix.
Access filters: prior authorisation experience; NUPCO and formulary constraints; self-pay share.
Persistence signals: reasons patients discontinue; monitoring burden; referral to bariatric surgery.

Modes: online quantitative with optional CATI; Arabic and English; depth interviews for KOLs and medical directors. Sample frames are stratified across endocrinology, family medicine, internal medicine, and bariatric surgery — the same specialty split highlighted in independent Saudi anti-obesity medicine research (PMC12366907). Deliverables include crosstabs, specialty segmentation, message implications, and forecast inputs. Scoped custom projects typically cost $10,000–$60,000.

Method

How we size and validate obesity market research in Saudi Arabia

→Physician survey sample frame stratified across endocrinology, family medicine, internal medicine, bariatric surgery, and obesity clinics, balanced by region and public or private sector.
→Depth interviews and quantitative validation on patient selection, initiation triggers, monitoring, switching, and the evidence that would change prescribing behaviour.
→Payer research with insurers and third-party administrators covering coverage policy, prior authorisation, and employer plan variation under Council of Health Insurance (CHI) rules.
→Patient journey research with screened treated and treatment-seeking respondents, focused on expectations, cost tolerance, and drivers of discontinuation.
→Bottom-up opportunity model reconciling eligible population, access route, initiation, and persistence, with pricing and access recommendations by sector and channel.

Why BioNixus

Why teams choose BioNixus for Saudi obesity market research

BioNixus brings global reach with local rigour — operating across the Americas, EMEA, and APAC with the country-level depth that generic research cannot replicate. Founded in regulated healthcare, we apply the same methodological standards to life sciences (pharma, biotech, medtech) and to adjacent sectors including B2B, FMCG, and industrial markets. We translate KOL, payer, and hospital evidence — and where relevant, buyer, channel, and consumer insight — into launch, access, and growth strategies built for board-level scrutiny.

✓Access is the core market-research question, because coverage inconsistency defines addressable volume for semaglutide and tirzepatide.
✓Persistence and discontinuation research with patients, which is where obesity forecasts most often fail when much demand is self-pay.
✓Coverage of pharmacotherapy, surgery, and clinic programmes, so a physician survey models route substitution instead of a single pathway.
✓Prescriber segmentation across endocrinology, primary care, and bariatric surgery, reflecting how initiation volume is distributed in the Kingdom.
✓Arabic and English fieldwork with clinicians and patients, coordinated from the Al Khobar office.
✓Senior-led custom studies, typically $10,000–$60,000, with a costed proposal returned within one working day.

Questions

Frequently asked questions

Who runs obesity GLP-1 market research in Saudi Arabia?

BioNixus runs custom obesity and GLP-1 market research in Saudi Arabia, including physician surveys, patient-journey work, and payer interviews, with fieldwork support from our Al Khobar office. Studies are scoped to the brand decision — not sold as a syndicated obesity report. Typical custom fees are $10,000–$60,000.

Can BioNixus run a GLP-1 physician survey in Saudi Arabia?

Yes. BioNixus fields GLP-1 physician surveys and KAP studies among endocrinologists, family physicians, internal medicine, and bariatric surgeons in Saudi Arabia, in Arabic and English, covering initiation, switching between semaglutide and tirzepatide, access barriers, and persistence.

Is semaglutide for weight loss reimbursed in Saudi Arabia?

Coverage is inconsistent. Public access depends on formulary and procurement pathways (including NUPCO-linked supply). Private cover varies by insurer and employer plan under Council of Health Insurance (CHI) rules, and a substantial share of demand is out of pocket. BioNixus verifies current coverage with payer and physician research rather than assuming a single national rule.

How do tirzepatide and semaglutide compete in the Saudi obesity market?

Both molecules sit inside the broader incretin and anti-obesity medicine conversation. Competitive share, indication mix (diabetes versus obesity), supply, and self-pay economics differ by specialty and sector. BioNixus measures that with molecule-level physician surveys and pharmacy and clinic channel work — not with a single headline market number.

What sample does a Saudi GLP-1 / AOM KAP survey need?

Design depends on the decision. Independent published work in Saudi Arabia has used national convenience samples of about 90 clinicians to compare specialties (see PMC12366907). BioNixus scopes sample size, quotas, and regions to the forecast or messaging question, and can add patient modules when persistence drives revenue.

How is BioNixus different from IQVIA or a syndicated obesity report for KSA GLP-1?

BioNixus delivers commissioned primary evidence — named methodology, specialty quotas, and decision-ready crosstabs — when syndicated audits cannot explain account-level or physician-level behaviour for semaglutide and tirzepatide in Saudi Arabia. Keep syndicated audits where they fit; brief BioNixus for custom HCP and access research ($10,000–$60,000 typical).

Where is BioNixus based for Saudi obesity research?

Saudi programmes are supported from our Al Khobar office, with additional hubs in Dubai (Thuraya Tower 1, 5th Floor, Al Sufouh 2), Cairo, London, Sheridan WY, and São Paulo.

Get a scoped proposal in 48 hours

Name the brand, the country, and the breakdown your syndicated feed cannot give you. We send a project- and country-priced proposal — typically within 48 hours.

Email us

US No. +1 888 465 5557Europe No. +44 7727 666682Middle East, Africa and Asia No. +20 120 688 2323